Clinical Trial: Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal Tumor

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational

Official Title: Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal Tumor

Brief Summary: Our study aims to evaluate the role of Dickkopf-4 as biomarkers in the treatment of gastrointestinal stromal tumor.

Detailed Summary: To identify whether Dickkopf-4 (DKK4) could be a potential biomarker for diagnosis and prognosis in patients with gastrointestinal stromal tumor (GIST). Serum was collected from 50 patients with GIST. Serological levels of DKK4 were examined by enzyme-linked immunosorbent assay (ELISA). The sensitivity and specificity was compared with modified NIH risk criteria. A 3-year follow-up was monitored to evaluate the correlation between DKK4 serum levels and relapse-free or overall survival. The expression of DKK4 in GIST tumor tissues was also evaluated using immunohistochemistry staining.
Sponsor: RenJi Hospital

Current Primary Outcome: Overall Survival [ Time Frame: 3 years ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Relapse-free Survival [ Time Frame: 3 years ]

Original Secondary Outcome: Same as current

Information By: RenJi Hospital

Dates:
Date Received: October 11, 2016
Date Started: October 2016
Date Completion: October 2019
Last Updated: October 11, 2016
Last Verified: October 2016